Recently, two large-scale studies examining chemical-genetic interactions between new or established anti-cancer treatments and cancer cell lines of known genotype demonstrated the promise of such top-down approaches by identifying previously unknown sensitivities of many cancer genotypes, such as between Ewing's sarcomas and PARP inhibitors [5], [6]. Here, PARP1 is linked to Ewing sarcoma.